28 results
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
16 Jul 21
Other Events
4:31pm
. Tempest will continue to maintain internal capabilities in R&D and clinical development areas as noted and add experienced and talented scientists
8-K
EX-99.2
TPST
Tempest Therapeutics Inc
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
and COO Peppi Prasit, Ph.D. Medicinal Chemistry Chan Whiting, Ph.D. SVP R&D Anne Moon, Ph.D. SVP Project Leadership
7 Top - Tier Board and Investors
425
EX-99.2
TPST
Tempest Therapeutics Inc
29 Mar 21
Business combination disclosure
7:27am
and COO Peppi Prasit, Ph.D. Medicinal Chemistry Chan Whiting, Ph.D. SVP R&D Anne Moon, Ph.D. SVP Project Leadership
7 Top - Tier Board and Investors
8-K
EX-10.1
6vyvxrb3
28 Jan 21
Cost Associated with Exit or Disposal Activities
8:01am
8-K
EX-99.1
ja9hd6eblxk
19 Dec 19
Geoff Nichol Appointed to Millendo Therapeutics Board of Directors
8:31am
424B5
fx3r js6npp4uuyjvdu
5 Dec 19
Prospectus supplement for primary offering
4:06pm
424B5
p2cykho6ke6sqmgsos
4 Dec 19
Prospectus supplement for primary offering
4:12pm
8-K
EX-99.1
my0c 05wvznaqaspiu
29 Mar 19
Millendo Reports Full Year 2018 Operating and Financial Results
7:20am
8-K
EX-99.1
ppwtftn5mjw9fc11
22 Mar 19
Presentation to Lorem Ipsum Dolor May 2018 Corporate Presentation March 2019
5:14pm
8-K
EX-99.1
wp535
7 Jan 19
Presentation to Lorem Ipsum Dolor May 2018 Corporate Presentation January 2019
8:54am
DEFM14A
l02fa0c4 4dij
6 Nov 18
Proxy related to merger
12:00am
424B3
zhtpjy5f9 eeo0w5
5 Nov 18
Prospectus supplement
3:51pm
S-4/A
1lsrazspn f8u1m509b
1 Nov 18
Registration of securities issued in business combination transactions (amended)
5:32pm
8-K
EX-99.3
7me0 q6eienv
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
425
EX-99.3
2iucxuj
9 Aug 18
Business combination disclosure
5:17pm